Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 study of nanvuranlat with or without durvalumab in unresectable or recurrent biliary tract cancer
jRCT2031260086Phase 1Recruiting
- Sponsor
- J-Pharma
- Start
- Jul 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of JPH203 in biliary cancer, extrahepatic cholangiocarcinoma (eCCA), intrahepatic cholangiocarcinoma (ICC) and 1 more (2 arms), sponsored by J-Pharma. Primary endpoint: Type and incidence of dose-limiting toxicities (DLTs). Started Jul 2026; status: recruiting.
02
Drugs
JPH203
03
Conditions
biliary cancerextrahepatic cholangiocarcinoma (eCCA)intrahepatic cholangiocarcinoma (ICC)gallbladder cancer
Beyond the preview
Go deeper on jRCT2031260086.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031260086.